TY - JOUR
T1 - Surveillance urodynamics for neurogenic lower urinary tract dysfunction
T2 - A systematic review
AU - Kavanagh, Alex
AU - Akhavizadegan, Hamed
AU - Walter, Matthias
AU - Stothers, Lynn
AU - Welk, Blayne
AU - Boone, Timothy B.
N1 - Funding Information:
Competing interests: Dr. Kavanagh has participated in advisory board meetings for Paladin Labs and has received a research grant from Astellas. Dr. Walter is a Michael Smith Foundation for Health Research Research Trainee Award recipient, in partnership with the Rick Hansen Foundation (Grant No. 17110); has received funding from Coloplast, Pfizer, Wellspect, and the Rick Hansen Institute; and has received travel awards from the International Continence Society, American Spinal Injury Association, British Columbia Regenerative Medicine, and Faculty of Medicine at the University of British Columbia. Dr. Stothers has participated in advisory board meetings for Astellas. Dr. Boone has participated in global advisory board meetings and has been a speaker for Astellas. The remaining authors reports no competing personal or financial interests related to this work.
Publisher Copyright:
© 2019 Canadian Urological Association.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/4
Y1 - 2019/4
N2 - Introduction: Baseline urodynamic characterization in patients with neurogenic lower urinary tract dysfunction (NLUTD) allows detection of unsafe storage and voiding pressures and optimization of these parameters through medical or surgical intervention. Surveillance urodynamics (sUDS) studies are performed in the ambulatory setting after baseline characterization, with the goal of monitoring bladder function. How often this study should be performed and the circumstances that should prompt repeated studies are unknown. The primary objective of this review is to evaluate the evidence supporting sUDS in the setting of NLUTD as assessed by whether the study leads to 1) change in patient management; 2) determination of new findings not suggested by imaging or symptoms; and 3) demonstration of superior outcomes compared to observation. The secondary objective is to review sUDS practice patterns among urologists in their assessment of NLUTD. Methods: PubMed, EMBASE, and Cochrane Library databases were reviewed for English-language literature published between January 1975 and March 2018. Results: Twenty-eight independent articles (1368 patients, 9486 patient-years of followup) were included. Given heterogeneous data, 49% of 263 subjects were asymptomatic, yet demonstrated sUDS abnormality prompting treatment. Eight cross-sectional studies (four spinal cord injury [SCI], two NLUTD, two spina bifida) surveyed urologists regarding current sUDS patterns; 53% of 498 respondents perform sUDS between one and three years. Conclusions: Evidence supporting optimal surveillance for NLUTD is lacking. Level 2b‒4 evidence suggests that sUDS is likely to modify patient treatment and often demonstrates findings that modify treatment in the absence of symptoms or imaging changes.
AB - Introduction: Baseline urodynamic characterization in patients with neurogenic lower urinary tract dysfunction (NLUTD) allows detection of unsafe storage and voiding pressures and optimization of these parameters through medical or surgical intervention. Surveillance urodynamics (sUDS) studies are performed in the ambulatory setting after baseline characterization, with the goal of monitoring bladder function. How often this study should be performed and the circumstances that should prompt repeated studies are unknown. The primary objective of this review is to evaluate the evidence supporting sUDS in the setting of NLUTD as assessed by whether the study leads to 1) change in patient management; 2) determination of new findings not suggested by imaging or symptoms; and 3) demonstration of superior outcomes compared to observation. The secondary objective is to review sUDS practice patterns among urologists in their assessment of NLUTD. Methods: PubMed, EMBASE, and Cochrane Library databases were reviewed for English-language literature published between January 1975 and March 2018. Results: Twenty-eight independent articles (1368 patients, 9486 patient-years of followup) were included. Given heterogeneous data, 49% of 263 subjects were asymptomatic, yet demonstrated sUDS abnormality prompting treatment. Eight cross-sectional studies (four spinal cord injury [SCI], two NLUTD, two spina bifida) surveyed urologists regarding current sUDS patterns; 53% of 498 respondents perform sUDS between one and three years. Conclusions: Evidence supporting optimal surveillance for NLUTD is lacking. Level 2b‒4 evidence suggests that sUDS is likely to modify patient treatment and often demonstrates findings that modify treatment in the absence of symptoms or imaging changes.
UR - http://www.scopus.com/inward/record.url?scp=85066278387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066278387&partnerID=8YFLogxK
U2 - 10.5489/cuaj.5563
DO - 10.5489/cuaj.5563
M3 - Review article
AN - SCOPUS:85066278387
VL - 13
SP - 133
EP - 141
JO - Canadian Urological Association Journal
JF - Canadian Urological Association Journal
SN - 1920-1214
IS - 4
ER -